Dermatology is the branch of medicine that specialises in the study of both normal and abnormal skin and its associated structures. Research and diagnosis of diseases, cancers, cosmetic and ageing conditions of the skin, fat, hair, nails, oral, and genital mucous membranes, are all aspects of dermatology. Healthcare professionals in this area regularly treat patients of all ages presenting with various inflammatory, inherited, environmental, occupational, or malignant skin disorders.
To date, there are approximately 2000 distinct diseases affecting the skin with many variants. Although many skin diseases are harmless and asymptomatic, others are associated with significant disability, increased morbidity, and reduced quality of life.
The dermatologist is involved in the treatment and prevention of a wide range of skin disorders. They employ various investigations to diagnose and medicine-based or surgical interventions to treat various types of skin conditions. These include, but are not limited to, dermatopathology, dermatologic and cosmetic surgery, topical and systemic medicines, immunotherapy, and phototherapy. As well as seeing patients in dermatology clinics, dermatologists act as consultants to other clinical specialists or perform clinical or basic research.
This Dermatology Speciality Hub is an expert educational resource, intended for healthcare professionals, that provides credible medical information in the form of Learning Zones. These Learning Zones provide self-directed medical education about common skin disorders such as skin cancer, urticaria, various types of psoriasis, and atopic dermatitis.
To find out more, navigate through the corresponding Learning Zones.
Related news and insights
Merck announced new and updated findings from the Phase III EORTC1325/KEYNOTE-054 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, as adjuvant therapy in resected, high-risk stage III melanoma.
Novartis announced detailed results from the Phase III COMBI-i trial evaluating the investigational immunotherapy spartalizumab (PDR 001) in combination with the targeted therapies Tafinlar (dabrafenib) and Mekinist (trametinib) compared to Tafinlar + Mekinist alone.
Eli Lilly and Company and Incyte announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for baricitinib for the treatment of adult patients with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
In this section of the guidelines of care for psoriasis, we will focus the discussion on ultraviolet (UV) light–based therapies, which include narrowband and broadband UVB, UVA in conjunction with photosensitizing agents...
This is an executive summary of all consented recommendations of the European Psoriasis Guidelines – Update 2015. The long version of this guideline is available online as supplementary file. A detailed...